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SYSTEMATIC REVIEW AND META-ANALYSIS
Implantable Cardioverter–Defibrillators in 
Trials of Drug Therapy for Heart Failure: 
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Salomé Carvalho, MD; Pedro Carmo, MD; Diogo Cavaco, MD; Francisco Belo Morgado, MD;  
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BACKGROUND: Medical therapy for heart failure with reduced ejection fraction evolved since trials validated the use of implant-
able cardioverter–defibrillators (ICDs). We sought to evaluate the performance of ICDs in reducing mortality in the era of mod-
ern medical therapy by means of a systematic review and meta- analysis of contemporary randomized clinical trials of drug 
therapy for heart failure with reduced ejection fraction.
METHODS AND RESULTS: We systematically identified randomized clinical trials that evaluated drug therapy in patients 
with heart failure with reduced ejection fraction that reported mortality. Studies that enrolled <1000 patients, patients 
with left ventricular ejection fraction >40%, or patients in the acute phase of heart failure and study treatment with 
devices were excluded. We identified 8 randomized clinical trials, including 31 701 patients of whom 3631 (11.5%) had 
an ICD. ICDs were associated with a lower risk of all- cause mortality (relative risk [RR], 0.85; 95% CI, 0.78–0.94) and 
sudden cardiac death (RR, 0.49; 95% CI, 0.40–0.61). Results were consistent among studies published before and 
after 2010. In meta- regression analysis, the proportion of nonischemic etiology did not affect the associated benefit 
of ICD.
CONCLUSIONS: In our meta- analysis of contemporary randomized trials of drug therapy for heart failure with reduced ejection 
fraction, the rate of ICD use was low and associated with a decreased risk in both all- cause mortality and sudden cardiac 
death. This benefit was still present in trials with new medical therapy.
Key Words: all-cause mortality ■ heart failure with reduced ejection fraction ■ implantable cardioverter–defibrillators ■ sudden cardiac 
death
In patients with heart failure with reduced ejection fraction (HFrEF), sudden cardiac death (SCD) is a major contributor for the burden of all- cause mortal-
ity.1 Medical therapy with modulators of neurohormo-
nal systems involved in the triggering and progression 
of HFrEF is the mainstay of the treatment to reduce the 
risks of SCD and all- cause mortality.2
Implantable cardioverter–defibrillators (ICDs) further 
reduce these risks and are currently recommended in 
patients with New York Heart Association functional 
class II or III and a left ventricular ejection fraction (LVEF) 
of 35% or less for the primary prevention of SCD and 
to prolong life.3–5 However, the rate of ICD use in clinical 
practice is suboptimal, even in populations enrolled in 
contemporary clinical trials of drug therapy for HFrEF.2,6 
We sought to evaluate the performance of ICDs in 
reducing SCD and all- cause mortality in populations 
enrolled in contemporary randomized clinical trials of 
drug therapy for HFrEF by means of a systematic re-
view and meta- analysis.
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METHODS
Search of the Studies
All data and materials have been made publicly avail-
able at the Dataverse Project and can be accessed at 
https://dataverse.harvard.edu/dataset.xhtml?persisten
tId=doi%3A10.7910%2FDVN%2FVU8QNE.
A systematic review and trial- level meta- analysis of 
randomized clinical trials that evaluated drug therapy 
in patients with HFrEF were performed according to 
the Preferred Reporting Items for Systematic reviews 
and Meta- Analyses guidelines.7 Potential trials were 
identified from PubMed, EMBASE, and CENTRAL 
(Cochrane Central Register of Controlled Trials) from 
December 1996, the date of the publication of the 
first clinical trial demonstrating the efficacy of ICD in 
reducing mortality,8 through February 8, 2019 using 
the following search terms ([heart failure OR cardiac 
failure OR cardiomyopathy] AND [reduced ejection 
fraction OR ejection fraction less OR systolic] AND 
[randomized OR randomised OR randomly] AND 
[mortality OR death]). We excluded studies enrolling 
<1000 patients, patients with left ventricular ejection 
fraction >40%, patients enrolled in the acute phase 
of heart failure, and study treatments with devices.
Data Extraction
Two authors (F.G., J.F.) independently assessed ti-
tles, abstracts, and full texts, when appropriate, for 
eligibility and data extraction. Disagreements were 
resolved by consensus or, if necessary, by a third au-
thor (F.C./J.C.). Details on the study design, patient 
characteristics, treatments, and outcome measures 
of all- cause death and SCD were collected from the 
main publication9–16 and subsequent subanalysis 
publications.2,17,18
Assessment of Risk of Bias
Two authors (J.C., F.C.) independently assessed 
the risk of bias within the trials using the Cochrane 
Collaboration risk- of- bias tool. The reviewers evalu-
ated the risk of bias as “low,” “high,” or “unclear” for 
the following 6 domains: random sequence genera-
tion, allocation concealment, participants and person-
nel blinding, outcome assessment blinding, selective 
reporting, and other sources of bias.
Statistical Analysis
Random effects were used to pool the relevant stud-
ies and summarize the evidence because of the vari-
ability of demographic, clinical, and pharmacologic 
treatment baseline characteristics among the in-
cluded study populations (Table 1). The results were 
presented as relative risk (RR) with 95% CIs. A 2- 
sided P<0.05 was considered significant.
We assessed for heterogeneity using the Cochran 
Q test, which was quantified by the I2 statistic. A fixed- 
effects model was additionally used in case of hetero-
geneity across studies.
We conducted sensitivity analyses in studies pub-
lished before and after 2008, studies including patients 
with LVEF 35% to 40% and only patients with LVEF 
<35%, and studies reporting the use of cardiac resyn-
chronization therapy (CRT) and not reporting the use of 
this device. We set the median of the search period of 
studies (January 2008) as the landmark to differentiate 
older from newer studies.
We performed random- effects meta- regression 
with the baseline characteristics of study populations 
(prevalence for categorical variables and mean/median 
value for continuous variables) as a covariate to assess 
their potential effects on the impact of the ICD on sud-
den death.
CLINICAL PERSPECTIVE
What Is New?
• Implantable cardioverter–defibrillator use was 
associated with reduced all-cause mortality 
and sudden cardiac death in patients enrolled 
in contemporary heart failure with reduced ejec-
tion fraction trials.
• Implantable cardioverter–defibrillator benefit 
was not influenced by nonischemic etiology.
• Implantable cardioverter–defibrillators were only 
used in 12% of patients.
What Are the Clinical Implications?
• Implantable cardioverter–defibrillator use still 
appears to reduce mortality among patients 
with heart failure with reduced ejection frac-
tion on top of contemporary optimal medical 
therapy.
• The findings support current implantable car-
dioverter–defibrillator guidelines.
Nonstandard Abbreviations and Acronyms
ACEI angiotensin-converting-enzyme inhibitors
ARB antiotensin-2 receptor blockers
CRT cardiac resynchronization therapy
HFrEF heart failure with reduced ejection 
fraction
ICD implantable cardioverter–defibrillator
LVEF left ventricular ejection fraction
SCD sudden cardiac death
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We looked for potential publication bias using funnel 
plots and Egger’s test.
The primary analyses were performed using 
RevMan version 5.3 (The Nordic Cochrane Center, The 
Cochrane Collaboration, Copenhagen, Denmark).
RESULTS
Studies Included
After manual screenings of the titles, abstracts, and full 
texts, we identified 8 studies that fulfilled the inclusion 
and exclusion criteria with outcome measures of inter-
est for patients with and without ICD (Figure 1). In the 
ATMOSPHERE (Aliskiren Trial to Minimize Outcomes 
in Patients with Heart Failure)16 study, the results were 
reported together for 1048 patients with ICDs and 107 
patients with isolated CRT pacemakers. The WARCEF 
(Warfarin versus Aspirin in Reduced Cardiac Ejection 
Fraction) study data refer to a propensity- matched 
analysis with the entire cohort of ICD patients and 
44.6% of the cohort without an ICD.18 
The SHIFT (Ivabradine and outcomes in chronic 
heart failure)
 study, although reporting univariable association of 
ICDs with all- cause mortality using a hazard ratio (HR) 
(0.85; 95% CI, 0.58–1.58) could not be included be-
cause of missing absolute data.19
We included a total of 31  701 patients in this 
analysis, of whom 3631 (11.5%) had an ICD. Table 1 
provides a comprehensive description of each in-
cluded study.
All- Cause Death
In 8 studies there were 715 deaths in 3631 patients 
(19.7%) with ICDs and 7086 deaths in 28 070 patients 
(25.2%) without ICDs (random- effects risk ratio, 0.85; 
95% CI, 0.78–0.94; I2=24%) (Figure  2). Mortality per 
100  patient/year was 8.00 and 9.84, respectively. 
Fixed- effects risk ratio was 0.86 (95% CI, 0.80–0.92) 
(Figure S1).
Sudden Cardiac Death
In 6 studies there were 91 SCDs in 2386 patients (3.8%) 
with ICDs and 1855 SCDs in 19 591 patients (9.5%) 
without ICDs (random- effects risk ratio, 0.49; 95% CI, 
0.40–0.61; I2=0%) (Figure  3). SCDs per 100  patient/
year was 1.74 and 3.79, respectively. Fixed- effects risk 
ratio was 0.48 (95% CI, 0.39–0.60) (Figure S2).
Sensitivity Analysis
The results were consistent among studies published 
before and after 2008, those that did or did not include 
patients with LVEF between 35% and 40%, and stud-
ies that did or did not report the use of CRT devices 
(Table 2). 
The sensitivity analysis for all- cause death after ex-
clusion of the ATMOSPHERE study showed similar re-
sults (RR, 0.83; 95% CI, 0.75–0.91; I2=11%).
Meta- Regression Analysis
Meta- regression analyses investigating the potential 
effects of demographic and clinical characteristics 
on the all- cause death associated with ICD com-
pared to no ICD revealed significant effects of atrial 
fibrillation (P=0.013), left ventricular ejection frac-
tion (P=0.040), and use of angiotensin- converting- 
enzyme inhibitors (ACEI) or antiotensin- 2 receptor 
blockers (ARB) (P=0.035) (Figure S3). There was no 
significant impact of age, sex, hypertension, diabe-
tes mellitus, nonischemic etiology, New York Heart 
Association III to IV functional classes, use of beta- 
blockers, or mineralocorticoid antagonists on the 
effect of ICDs on all cause- death.
Risk of Bias
All of the included studies did not randomize ICD im-
plantation. No publication bias was found using visual 
inspection of a funnel plot and an Egger test (P= 0.302) 
(Figure S4).
DISCUSSION
In this systematic review and meta- analysis of contem-
porary clinical trials for drug therapy of HFrEF, the use 
of ICDs was scarce but associated with a significant 
Figure 1. Flowchart diagram illustrating studies selection 
methodology.
ICD indicates implantable cardioverter–defibrillator; and RCT, 
randomized clinical trial.
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reduction in all- cause death and SCD when compared 
to no use.
Current guidelines supporting ICD implantation for 
primary prevention are backed up on long- standing 
trials, namely, the MADIT II (Multicenter Automatic 
Defibrillator Implantation Trial II)20 and the SCD- HeFT 
(Sudden Cardiac Death in Heart Failure Trial)3 that 
showed up to a 31% reduction in all- cause mortal-
ity. However, HFrEF patients faced dramatic changes 
over time regarding epidemiology, etiology, and 
optimal medical therapy concept, including beta- 
blockers, ACEI/ARB, mineralocorticoid antagonists, 
sacubitril- valsartan, and even mechanical support 
concerning end- stage heart failure. These medical 
advances culminated in the progressive reduction of 
all- cause death and SCD,2 challenging the present ad-
ditional benefit of ICDs.
Our study analyzed contemporary randomized clin-
ical trials that were performed within a highly selected 
population where those with significant comorbidities, 
such as significant renal or hepatic diseases and any 
other condition that substantially reduces life expec-
tancy, are often excluded and where compliance to-
ward optimal medical therapy is assured in greater 
Figure 2. Forest plots comparing patients with ICD vs without ICD for the outcome all- cause death.
Pooled estimates were calculated by random effects. ATMOSPHERE indicates Aliskiren Trial to Minimize Outcomes in Patients 
with Heart Failure; BEST, Beta-Blocker Evaluation of Survival Trial; CHARM- Added, Candesartan in Heart Failure: Assessment of 
Reduction in Mortality and Morbidity - Added Trial; CHARM- Alt, Candesartan in Heart Failure: Assessment of Reduction in Mortality 
and Morbidity - Alternative Trial; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; EMPHASIS- HF, Eplerenone in 
Mild Patients Hospitalization and Survival Study in Heart Failure; ICD, implantable cardioverter–defibrillator; M–H, Mantel-Haenszel 
methods; PARADIGM- HF, Prospective Comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-
Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial; and WARCEF, Warfarin 
versus Aspirin in Reduced Cardiac Ejection Fraction.
Figure 3. Forest plots comparing patients with ICD vs without ICD for the outcome sudden cardiac death.
Pooled estimates were calculated by random effects. CHARM- Added indicates Candesartan in Heart Failure: Assessment of 
Reduction in Mortality and Morbidity - Added Trial; CHARM- Alt, Candesartan in Heart Failure: Assessment of Reduction in Mortality 
and Morbidity - Alternative Trial; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; EMPHASIS- HF, Eplerenone in 
Mild Patients Hospitalization and Survival Study in Heart Failure; ICD, implantable cardioverter–defibrillator; M–H, Mantel-Haenszel 
methods; PARADIGM- HF, Prospective Comparison of ARNI (Angiotensin Receptor-Neprilysin Inhibitor) with ACEI (Angiotensin-
Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial; and WARCEF, Warfarin 
versus Aspirin in Reduced Cardiac Ejection Fraction.
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proportion than in a real- word setting. This investi-
gation showed a relative reduction both in all- cause 
death and SCD by 15% and 50%, respectively, on top 
of the optimal conditions associated with the use of 
ICDs. These results are consistent with previous stud-
ies,3,4,20 even though a theoretic different HFrEF pop-
ulation sample. 
The absence of significant heterogeneity among 
the studies analyzed emphasizes the association be-
tween ICD use and lower risk of all- cause death. The 
RR of all- cause death was not favorable to the use of 
ICD only in the CHARM (Candesartan in Heart Failure: 
Assessment of Reduction in Mortality and morbidity) 
Alternative study, which may be related to the small 
number of ICD patients, only 68, that may have gen-
erated a random distribution effect on events. In the 
SHIFT study, ICD use was also associated with 15% 
RR reduction in all- cause death,19 which is superim-
posable to that observed in our meta- analysis. The 
association with reduced risk of SCD revealed no het-
erogeneity among the 6 studies included in the anal-
ysis. The lower risk of SCD observed in ICD patients 
should be framed in a possible context of perceived 
higher risk of death in these patients. Despite the 
fact that PARADIGM HF (Prospective Comparison of 
ARNI [Angiotensin Receptor-Neprilysin Inhibitor] with 
ACEI [Angiotensin-Converting Enzyme Inhibitor] to 
Determine Impact on Global Mortality and Morbidity 
in Heart Failure Trial) and ATMOSPHERE have ex-
cluded patients with ventricular arrhythmias occurring 
3 months prior to screening that were untreated, it is 
possible that ICD implantation has been performed 
for the secondary prevention of sudden death, and 
no study has excluded these patients.9–16 The rates of 
recurrent ventricular arrhythmias and mortality remain 
high in patients who received an ICD for secondary 
prevention.21 
The growing adherence of evidence- based heart 
failure medication throughout the years should be 
highlighted.  When comparing the older (BEST [Beta-
Blocker Evaluation of Survival Trial], CHARM- Added, 
and CHARM- Alternative)9–11 against the newer trials 
(PARADIGM- HF and ATMOSPHERE),15,16 both beta- 
blockers and mineralocorticoid antagonists almost 
doubled their compliance rates. It is a different case 
scenario regarding ACEI/ARB adherence because it 
remained persistently high from early trials, with the ex-
ception of CHARM- Alternative,11 where half of the pop-
ulation with intolerance to ACEI received an ARB, and 
ATMOSPHERE,16 where 2 of 3 patients were on ACEI, 
although all received a renin- angiotensin- aldosterone 
system inhibitor blockage (enalapril and/or aliskiren). 
Since 2008, the utilization rate of ACEI/ARB was 
>93%, beta- blockers >86%, and mineralocorticoid an-
tagonists >50%. However, sensitivity analysis did not 
reveal significant differences in all- cause death or SCD 
in studies published either before9–12 or after 2008.13–16 
These results reinforce the impact of ICD on prevent-
ing sudden death, even in patients with contemporary 
guideline optimal medical therapy. The results were 
also consistent in studies that included patients with 
LVEF between 35% and 40%. As the indication for ICD 
is based on the presence of LVEF <35%, the inclusion 
of patients with LVEF between 35% and 40% in the 
group without ICD and therefore with a lower risk of 
SCD could reduce its benefit in these studies.
The reproducibility of our results is shown in the re-
cently published real- word SwedeHF (Swedish Heart 
Failure) Registry that enrolled 1305 patients fulfilling 
European Society of Cardiology criteria for ICD implan-
tation for primary prevention.22 After 1:1 propensity 
score matching to non- ICD recipients, all- cause mor-
tality risk within 1 and 5 years reduced 27% and 12%, 
respectively. The results were consistent with all sub-
group analysis, but data on SCD were not reported. 
The ICD rate of use was 11.5%, which is low for a 
class I recommended treatment in patients with HFrEF.5 
However, the use of this device therapy consistently in-
creased >4- fold between studies published before and 
after 2008. One study reported improvement in LVEF, 
limited life expectancy, New York Heart Association func-
tional class IV, and patient refusal as the main causes for 
nonimplantation of ICDs.23 Patients with HFrEF followed 
Table 2. Sensitivity Analysis for Studies Published Before 
and After 2010 and Studies That Did or Did Not Include 
Patients With LVEF Between 35% and 40%
Risk Ratio and 
95% CI
P Value for 
Interaction
All- cause death
Studies published before 2008 0.88 (0.75–1.04) 0.57
Studies published after 2008 0.83 (0.73–0.94) ···
Studies with EF 35% to 40% 
patients
0.89 (0.79–0.99) 0.27
Studies with only EF <35% 
patients
0.79 (0.65–0.94) ···
Studies reporting the use of CRT 0.86 (0.76–0.98) 0.70
Studies not reporting the use 
of CRT
0.83 (0.72–0.96) ···
Sudden cardiac death
Studies published before 2008 0.66 (0.45–0.97) 0.09
Studies published after 2008 0.44 (0.34–0.56) ···
Studies with LVEF 35% to 40% 
patients
0.52 (0.38–0.73) 0.89
Studies without LVEF 35% to 
40% patients
0.51 (0.35–0.74) ···
Studies reporting the use of CRT 0.41 (0.31–0.55) 0.08
Studies not reporting the use 
of CRT
0.60 (0.44–0.81) ···
CRT indicates cardiac resynchronization therapy; EF, Ejection Fraction; 
and LVEF, left ventricular ejection fraction. 
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in primary health care are less often referred for ICD im-
plantation because of the poor perception of benefits 
against contraindications.22 The implementation of qual-
ity control and performance measure programs has been 
shown to increase adherence to the primary prevention 
of SCD with ICD.6 Only 3 studies, all published after 2008, 
reported the use of CRT, whose prevalence ranged from 
5.6% to 8.5%.13,15,16 Although CRT amplifies the benefit 
of ICD in reducing mortality in patients with HFrEF,24 our 
sensitivity analysis with studies reporting the use of CRT 
showed no significant differences in all- cause death or 
SCD compared to studies not reporting the use of CRT.
Meta- regression analyses demonstrated that in-
creasing the proportion of patients with atrial fibrillation 
attenuates the benefit of ICD in reducing death from 
any cause. In patients with HFrEF, atrial fibrillation has 
been described as a marker of disease severity,25 so 
its presence may lead to a higher risk of death from 
pump failure, with the consequent lower benefit of ICD 
in reducing mortality.26
Clinical trials with lower LVEF mean values showed a 
greater reduction in all- cause death associated with ICD 
use, which is in line with the inverse relationship between 
LVEF and the risk of SCD described in the literature.27,28
Widespread use of ACEI/ARB was associated with 
a lower risk of all- cause death in patients with ICD 
compared to patients without ICD, highlighting the 
complementarity of pharmacological therapy with de-
vices in patients with HFrEF. In a post hoc analysis of 
the COMPANION (Comparison of Medical Therapy, 
Pacing, and Defibrillation in Heart Failure) trial, the au-
thors reported that both ACEI and ARB lowered the 
risk of appropriate ICD therapy, thus demonstrating a 
synergistic effect between these therapies.29 
An important issue regarding the effectiveness of 
ICDs is the relative uncertainty of their benefit in reducing 
all- cause death in patients with nonischemic HFrEF.30 
The WARCEF study was the only study that published 
results on the relative benefit of ICD use compared to 
nonuse on all- cause death in patients with nonisch-
emic etiology.18 The use of ICD was associated with no 
significant benefit on all- cause death in those patients 
(HR, 0.984; 95% CI, 0.641–1.509; P=0.941), unlike that 
observed in patients with ischemic etiology (HR, 0.640; 
95% CI, 0.448–0.915; P=0.015). Notwithstanding these 
facts, meta- regression analysis showed no significant 
correlation between changes in the proportion of non-
ischemic etiology and the relative benefit on all- cause 
death of ICD use compared to nonuse. 
Limitations
This is a meta- analysis of aggregate data from esti-
mates of individual studies, and therefore individual par-
ticipant data were not available. Although the studies 
have different designs, populations, pharmacological 
treatments, and follow- up, any significant heterogene-
ity on the reported outcomes was not found, and sen-
sitivity analyses were consistent with the main results. 
In the absence of randomization, it is possible that pa-
tients without ICD could have more comorbidity than 
patients with ICDs, leading to higher all- cause death. 
However, it is well known that patients enrolled in clini-
cal trials generally do not have many comorbidities, 
which is confirmed by the baseline characteristics of 
the population with and without ICD before propen-
sity matching included in the WARCEF study.18 The 
clinical trials included in this systematic review and 
meta- analysis did not report the type of ICD implanted 
or the incidence of appropriate and inappropriate 
shocks during the study follow- up. Recognizing that 
ICD shocks have a negative impact on prognosis31 
and the subcutaneous ICD is for selected patients,32 
the inclusion of these variables in sensitivity analyses 
could bring new insights to the results. Finally, the use 
of CRT in ICD patients may have amplified the benefit 
of this device, although concomitant use was relatively 
low. 
CONCLUSIONS
In our meta- analysis of contemporary randomized tri-
als of drug therapy for HFrEF, the rate of ICD use was 
low. The use of ICDs was associated with significant 
reductions in all- cause death and SCD, and the results 
were consistent in all sensitivity analyses. Our results 
call for the need to adhere to the current guidelines for 
the management of HFrEF.
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Figure S1. Fixed-effects Risk Ratio for All-Cause Death. 
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Figure S2. Fixed-effects Risk Ratio for Sudden Cardiac Death. 
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Figure S3. Meta-regression analysis on all-cause death.  
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Figure S4. Risk of Bias analysis. 
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